Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

20-Year study sheds light on rare breast tumor outcomes

NCT ID NCT07636096

Knowledge-focused Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviewed medical records of about 3,500 patients with phyllodes tumors, a rare type of breast tumor, treated at 8 top hospitals in China between 2001 and 2023. Researchers aim to describe the tumor features, treatments used, and long-term outcomes like recurrence and survival. Because phyllodes tumors are uncommon and most prior research focused on Western patients, this study provides much-needed data from a large Asian population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could improve understanding of phyllodes tumors in Asian populations and help guide personalized treatment and clinical guidelines.
What could go wrong
This is a retrospective study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other populations or change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

3,500 people

The number who actually took part.

Started

May 2026

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study includes patients who underwent surgical resection for breast phyllodes tumor (PT) at one of eight tertiary hospitals in China between January 1, 2001, and December 31, 2023. All patients with a postoperative paraffin-embedded pathology diagnosis of benign, borderline, or malignant PT according to WHO criteria are included. Exclusion criteria are: (1) PT with uncertain behavior or unclassified grade; (2) history of prior malignancy (excluding breast cancer) with less than 5 years disease-free survival, or concurrent diseases that may affect endpoint assessment; (3) loss to follow-up or missing critical data (pathological grade, surgical procedure, or follow-outcome). A total of approximately 3,500 eligible patients from eight participating centers will be enrolled. All patients are of Chinese ethnicity.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Breast phyllodes tumors (benign, borderline, or malignant) based on postoperative paraffin pathology according to WHO criteria * Underwent surgical treatment * Complete or substantially complete clinical records, pathology reports, and follow-up data Exclusion Criteria: * Phyllodes without histological grading * Hstory of other concomitant diseases that may affect the assessment of the study endpoint events * Patients lost to follow-up or with missing key data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast phyllodes tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast phyllodes tumor malignant breast phyllodes tumor phyllodes tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Phyllodes breast tumor Prognosis

Contacts and locations

Locations

  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong, 510120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.